RUNX3 and central nervous system cancer: The overall results of our current study, together with the hypermethylation of RUNX3 observed in our earlier investigation, indicate that epigenetic silencing of Wnt antagonists may constitute a crucial mechanism of abnormal up-regulation of this signaling pathway which is often observed in gliomas.